

SAKK Presentations at ICML 2025

SAKK trials

Trial: SAKK 38/19

Title: Feasibility of ctDNA and PET guided therapy in untreated DLBCL. Preliminary results of the SAKK 38/19 phase II trial

Speaker: Anastasios Stathis

Type of presentation: Oral presentation

Number: 006

Session name: PLENARY SESSION

Date and time: Wednesday, 18.06.2025, 14:25-14:40

Room: Room A, broadcast in all rooms

Trial: SAKK 38/19

Title: Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma

Speaker: Deborah Piffaretti

Type of presentation: Oral presentation

Number: 060

Session name: GENOMICS AND CLONAL HEMATOPOIESIS

Date and time: Thursday, 19.06.2025, 16:45 - 17:00

Room: Polivalente room, East Campus USI

Intergroup

Trial: CLL 18

Title: CLL18/MOIRAI trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in treatment-naïve CLL/SLL

Speaker: Paula Cramer

Type of presentation: Oral presentation

Number: OT2

Session name: ONGOING TRIALS

Date and time: Wed, 18.06.2025, 17:10 – 17:20

Room: Cinema Corso

Trial: TRIANGLE

Title: Ibrutinib added to MCL treatment has strong impact on MRD response and disease kinetics: results from the TRIANGLE trial



Speaker: Mouhamad Khouja

Type of presentation: Oral presentation

Number: 137

Session name: MANTLE CELL LYMPHOMA

Date and time: Thursday, 19.06.2025, 18:05 – 18:15

Room: Room B

Trial: HD18, HD21

Title: Imaging Biomarkers for the Definition of Response in the GHSG HD18, GHSG HD21 and LYSA AHL2011 Trials for Advanced-stage Hodgkin Lymphoma

Speaker: Justin Ferdinandus

Type of presentation: Oral presentation

Number: 012

Session name: IMAGING AND RADIOMICS

Date and time: Thursday, 19.06.2025, 09:30 – 09:45

Room: Room B, Broadcast in Marquee Parco Ciani